

Neurology Volume 66(2) Supplement 1 January 24, 2006

Inclusion-body myositis: Clinical and pathologic aspects, and basic research potentially relevant to treatment.

Askanas, Valerie MD, PhD; Dalakas, Marinos C. MD; Engel, W King MD
[Preface] Si

2

pg. S1-S6

A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes.

Finch, Caleb E. PhD

3

pg. S7-19

The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting.

Ciechanover, Aaron MD, DSc

4

pg. S20-S29

Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects.

Engel, W King MD; Askanas, Valerie MD, PhD

5

pg. S30-S32

The current status of treatment for inclusion-body myositis.

Griggs, Robert C. MD, FAAN

6

pg. S33-S38

Inflammatory, immune, and viral aspects of inclusion-body myositis.

Dalakas, Marinos C. MD

[Articles]

7

pg. S39-S48

Inclusion-body myositis: A myodegenerative conformational disorder associated with A[beta], protein misfolding, and proteasome inhibition.

Askanas, Valerie MD, PhD; Engel, W King MD

8

pg. S49-S55

Mitochondrial abnormalities in inclusion-body myositis.

Oldfors, A MD, PhD; Moslemi, A R. PhD; Jonasson, L; Ohlsson, M MD; Kollberg, G MSc; Lindberg, C MD, PhD

9

pg. S56-S58

Controlling autoimmunity in sporadic inclusion-body myositis.

Steinman, Lawrence MD

10

pg. S59-S64

Immunotherapeutic relief from persistent infections and amyloid disorders.

McGavern, Dorian B. PhD

11

pg. S65-S68

Inclusion-body myositis and Alzheimer disease: Two sides of the same coin, or different currencies altogether?

Murphy, M Paul PhD; Golde, Todd E. MD, PhD

12

pg. S69-S73

Amyloidogenic processing of [beta]-amyloid precursor protein in intracellular compartments.

Vetrivel, Kulandaivelu S. PhD; Thinakaran, Gopal PhD

13

pg. S74-S78

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis.

Glabe, Charles G. PhD; Kaye, Rakez PhD

14

pg. S79-S85

Apolipoprotein E and Alzheimer disease.

Huang, Yadong MD, PhD

15

pg. S86-S92

Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies.

van Leeuwen, F W. PhD; van Tijn, P MSc; Sonnemans, M A.F. BSc; Hobo, B BSc; Mann, D M.A. PhD; Van Broeckhoven, C PhD; Kumar-Singh, S MD, PhD; Cras, P MD, PhD; Leuba, G PhD; Savioz, A PhD; Maat-Schieman, M L.C. MD, PhD; Yamaguchi, H MD, PhD; Kros, J M. MD, PhD; Kamphorst, W MD, PhD; Hol, E M. PhD; de Vos, R A.I. MD; Fischer, D F. PhD

16

pg. S93-S96

Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases.

Davies, Kelvin J.A. PhD, DS; Shringarpure, Reshma PhD

17

pg. S97-S101

Brain and brawn: Parallels in oxidative strength.

Moreira, P I. MA; Honda, K MD, PhD; Zhu, X PhD; Nunomura, A MD, PhD; Casadesus, G PhD; Smith, M A. PhD; Perry, G PhD

18

pg. S102-S109

The unfolded protein response: A stress signaling pathway critical for health and disease.

Zhang, Kezhong PhD; Kaufman, Randal J. PhD

19

pg. S110-S113

Treatment and prevention of the amyloidoses: Can the lessons learned be applied to sporadic inclusion-body myositis?

Buxbaum, Joel N. MD

20

pg. S114-S117

RNA interference as potential therapy for neurodegenerative disease: Applications to inclusion-body myositis?

Paulson, Henry MD, PhD

21

pg. S118-S122

Developing therapeutics for the diseases of protein misfolding.

May, Barnaby C.H. PhD; Govaerts, Cedric PhD; Cohen, Fred E. MD, PhD

22

pg. S123-S124

Pilot trial of etanercept in the treatment of inclusion-body myositis.

Barohn, R J. MD; Herbelin, L BS; Kissel, J T. MD; King, W PT; McVey, A L. MD; Saperstein, D S. MD; Mendell, J R. MD